Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Diabetes treatment has evolved from insulin to metformin and GLP-1 receptor agonists, with drugs progressively advancing from short-acting to long-acting formulations
Serious & unknown risks Not established The Phase 2 trials didn't turn up an unexpected serious safety signal, but they were short
10% have taken one previously, but no longer do
With a seven-day half-life, that works out to 28 to 35 days
It works by mimicking GLP-1, a natural hormone that regulates appetite, slows digestion, and stabilizes blood sugar
As of 2026, BPC-157 is not approved by any regulatory authority (FDA, EMA, ANSM)
US$ 26.55
US$ 20.56
US$ 24.74
